MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire January 12, 2026 ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update […]